In vitro phase-I and reactive metabolites of X-376.
MS scan | Most abundant fragment ions | Rt.a (min) | Metabolic reaction | |
---|---|---|---|---|
X-376 | 547 | 447, 357, 257, 138 | 38.9 | Main drug |
Phase-I metabolites | ||||
M1 | 533 | 447, 343, 257, 138 | 38.0 | N-Demethylation at the piperazine ring |
M2 | 549 | 449, 359, 259, 139 | 35.6 | Reduction metabolic reaction in the amide group attached to the pyridazine ring |
M3 | 561 | 447, 371, 257, 138 | 44.1 | Oxidation at the piperazine ring |
M4 | 563 | 447, 373, 257, 138 | 42.0 | Hydroxylation at the piperazine ring |
Reactive metabolites | ||||
M5 | 572 | 472, 282, 120, 104 | 39.2 | Cyano addition at the pyridazine ring |
M6 | 588 | 472, 282, 104 | 42.9 | Hydroxylation at the piperazine ring and cyano addition at the pyridazine ring |
M7 | 852 | 496, 357, 257, 176 | 28.9 | Defluorination, hydroxylation, oxidation, and GSH conjugation |
Rt., retention time.